Loading company
Denali Therapeutics Inc.
DNLI · Nasdaq · ·
Next earnings: November 5, 2026
$20.82-0.8%Sep 29 close
- 1M
- -13.2%
- 6M
- +15.2%
- 1Y
- +43.4%
- 5Y
- -59.8%
DNLI · Nasdaq · ·
Next earnings: November 5, 2026
$20.82-0.8%Sep 29 close
Denali Therapeutics Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $3.6M | $0.00 | — |
| Profit | -$127.6M | -$124.1M | -2.77% |
| Profit per share | -$0.68 | -$0.72 | +5.56% |
| Free Cash Flow | -$97.8M | -$79.6M | -22.91% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are excited by the positive response to our AVLAYAH launch from the Hunter syndrome community and the physicians caring for these patients. It reflects years of partnership with patients, families, advocacy organizations and investigators, together with the outstanding execution of our commercial team,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Denali Therapeutics Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Denali Therapeutics Inc. has no earnings call transcript available.